Valuation : Neurogene Inc.

Market Cap 758M 651M 614M 559M 1.05B 72.11B 1.05B 7.26B 2.81B 36.75B 2.85B 2.78B 116B P/E 2026 *
-6.69x
P/E 2027 * -7x
Enterprise Value 465M 400M 376M 343M 642M 44.24B 644M 4.45B 1.72B 22.55B 1.75B 1.71B 71.32B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Neurogene Inc.

1 day-0.66%
1 week+0.03%
Current month+4.53%
1 month+6.14%
3 months+32.45%
6 months+70.86%
Current year+83.88%
1 week 36.56
Extreme 36.5573
40.42
1 month 30.57
Extreme 30.57
42.01
Current year 15.93
Extreme 15.93
43.66
1 year 15.93
Extreme 15.93
43.66
3 years 6.88
Extreme 6.875
74.49
5 years 6.88
Extreme 6.875
74.49
10 years 6.88
Extreme 6.875
74.49
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Sell

Chairperson

-4,200 0.0270%
7/2/26 Sell

Chairperson

-4,061 0.0261%
5/6/26 Sell

Chairperson

-9,600 0.0616%
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%+0.03%+94.76% - 763M
-3.24%-6.89%-5.65%+11.20% 48.01B
+0.17%-1.04%+405.80%+546.58% 44.44B
-0.86%-0.53%+36.92%+20.35% 42.67B
-0.14%-2.13%+1.31%+82.21% 39.96B
0.00%-2.61%+13.09%+42.33% 32.75B
-3.44%+0.22% - - 17.74B
-0.78%+0.53%+19.14%+116.26% 16.49B
-0.37%-0.87%+10.98%+30.93% 14.38B
-0.86%-1.41%+71.82%+39.36% 13.4B
Average -1.02%-0.41%+72.02%+111.15% 27.06B
Weighted average by Cap. -1.04%-1.10%+84.34%+131.92%

Financials

2026 *2027 *
Net sales - -
Net income -138M -118M -111M -102M -190M -13.09B -191M -1.32B -509M -6.67B -516M -505M -21.1B -147M -127M -119M -109M -203M -14.01B -204M -1.41B -546M -7.14B -553M -541M -22.59B
Net Debt -293M -252M -237M -216M -404M -27.87B -406M -2.81B -1.09B -14.21B -1.1B -1.08B -44.93B -180M -155M -146M -133M -249M -17.15B -250M -1.73B -668M -8.74B -677M -662M -27.65B
Logo Neurogene Inc.
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Employees
131
Date Price Change Volume
26-09-09 US$37.88 -0.66% 193,176
26-09-08 US$38.13 -1.22% 228,474
26-09-04 US$38.60 +2.63% 205,633
26-09-03 US$37.61 -1.96% 255,221
26-09-02 US$38.36 +1.29% 252,961
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
37.88USD
Average target price
80.43USD
Spread / Average Target
+112.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NGNE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!